Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Isabel Preeshagul, DO, MBS, discusses frontline treatment selection for patients with SCLC and significant FDA approvals in this disease.

Komal Jhaveri, MD, FACP, discusses the success of the INAVO120 trial of inavolisib/palbociclib/fulvestrant in PIK3CA-mutated metastatic breast cancer.

D-VRd has the potential to significantly improve clinical outcomes in transplant-ineligible or -deferred patients with newly diagnosed multiple myeloma.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Treatment with cilta-cel led to improvements across several QOL subscales compared with SOC therapy in patients with lenalidomide-refractory myeloma.

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Raajit Rampal, MD, discusses typical clinical applications of the 4 FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.

Here is your snapshot for all therapeutic options that were approved by the FDA in March 2025 spanning tumor types.

Experts from across oncology specialties discuss the long-term effects of the COVID-19 pandemic on patient care.

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

Raajit Rampal, MD, PhD, discusses current JAK inhibitor treatment options for myelofibrosis and additional therapies being evaluated in clinical trials.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Raajit Rampal, MD, discusses the variety of agents in phase 3 trials for the treatment of patients with myelofibrosis.

Rachel N. Grisham, MD, discusses the efficacy of avutometinib plus defactinib in patients with advanced or recurrent gynecologic mesonephric cancer.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

William D. Tap, MD, discusses the FDA approval of vimseltinib for patients with symptomatic TGCT and this agent's role in the treatment paradigm.

Dr Jhaveri discusses advice for managing inavolisib-related adverse effects and best practices for biomarker testing in patients with HR+ breast cancer.

Drs Geyer and Jabbour discuss ponatinib in Ph+ ALL, data with this agent plus blinatumomab, and how the safety profile of ponatinib affects its use.

Leveraging synthetic lethal approaches in lung cancer with new targets and agents may be a promising avenue of investigation.

Michael Foote, MD, discusses the use of EGFR inhibitors in the first vs subsequent lines of therapy for patients with metastatic colorectal cancer.

Frontline nivolumab plus chemotherapy elicited clinically meaningful long-term survival benefits vs chemotherapy alone in advanced gastric/GEJ cancer.

Dr Schram discusses the significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Dr Harding discusses the significance of the FDA approval of zanidatamab for patients with HER2-positive metastatic biliary tract cancer.

Here is your snapshot of all therapeutic options greenlit by the FDA in December 2024 spanning tumor types.

Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

Sara Hurvitz, MD, of Fred Hutch Cancer Center, and Neil Iyengar, MD, of Memorial Sloan Kettering Cancer Center, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.